Abstract:<p>One of the most prevalent forms of dementia is Alzheimer's disease (AD) which causes severe memory impairment within humans. As such, research into the early diagnosis of AD is essential to help treatment, which has led to significant advances in fluorescence imaging. Unfortunately, modern medicine and biology place increasingly strict requirements for fluorescent probes. Therefore, over recent years, researchers have taken strides to develop novel fluorescent molecular probes, with properties suitable for modern clinical applications, including low phototoxicity, weak background interference, deep tissue penetration, enhanced specificity, strong binding affinity, and suitable permeability through the blood–brain barrier (BBB). From these recent research results, many novel concepts for molecular design and fluorescence techniques have emerged. Herein, we present strategies towards the development of probes capable of meeting the advanced clinical requirements. As part of this review, we will summarize the characteristic enzymes and proteins involved in AD progression, including Amyloid-β, β-secretase, tau protein, monoamine oxidases, and methionine sulfoxide reductase. Then, we will evaluate some of the early probes and summarize the recent advancements made in the design of probes suitable for clinical applications, from which several strategies have emerged, such as increasing permeability to the blood–brain barrier, enhancing specificity by boosting binding affinity, and improving optical properties for <em>in vivo</em> imaging, etc. Then to conclude current strategies for early stage diagnosis of AD will be presented, and the opportunities as well as the remaining challenges will be outlined.</p>

Fluorescence Detection and Dissociation of Amyloid‐β Species for the Treatment of Alzheimer's Disease

Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects

Advances in development of fluorescent probes for detecting amyloid-β aggregates

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Strategies for Measuring Concentrations and Forms of Amyloid-Β Peptides

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

Shedding Light on Alzheimer's Disease: Recent Advances in Highly Selective Fluorescent Probes

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Photothermal and Photodynamic Therapies Via NIR-Activated Nanoagents in Combating Alzheimer's Disease.

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

An AIE-active Theranostic Probe for Light-Up Detection of Aβ Aggregates and Protection of Neuronal Cells.

Design of Self-Assembled Nanoparticles As a Potent Inhibitor and Fluorescent Probe for Β-Amyloid Fibrillization.

Fluorescent Peptide Nanoparticles to Monitor Aβ Oligomers

Targeting Β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes.

Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer’s disease

Fluorescent Peptide Nanoparticles to Detect Amyloid-Beta Aggregation in Cerebrospinal Fluid and Serum for Alzheimer's Disease Diagnosis and Progression Monitoring

Treatment of Alzheimer's disease with small-molecule photosensitizers

Design of aggregation-induced emission-active fluorogen-based nanoparticles for imaging and scavenging Alzheimer's -amyloid by photo-oxygenation

Novel strategies for the fight of Alzheimer's disease targeting amyloid- protein

Treatment of Alzheimer&rsquo;s Disease by Promoting the Aggregation of Small &Amp;beta;-Amyloid Peptides

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules